Menu
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Roche Holding AG Basel American Depositary Shares (OP:RHHBY)

51.94 +0.08 (+0.15%)
Streaming Delayed Price Updated: 4:00 PM EDT, May 20, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Roche Holding AG Basel American Depositary Shares

< Previous 1 2
...
24 25 26 27 28 29 30 31 32
...
36 37 Next >
News headline image
The Week Ahead In Biotech (Jan 31-Feb 5): Merck, Bristol-Myers Squibb, Lilly & Novartis Headline Large-Cap Biopharma Earnings News ↗
The broader market weakness pervaded into the biotech sector in the week ending Jan. 28, sending stocks lower. 
Via Benzinga
News headline image
FDA Approves First Injectable Eye Medicine For Vision Loss Disorder - Genentech's Vabysmo ↗
The FDA has approved Genentech's, a unit of  
Via Benzinga
News headline image
FDA Approves Genentech’s Vabysmo, the First Bispecific Antibody for the Eye, to Treat Two Leading Causes of Vision Loss
From Genentech
Via Business Wire
News headline image
Drug Troubles ↗
The drug sector has both good news and bad. 
Via Talk Markets
News headline image
Genentech's Evrysdi Application Under FDA Priority Review For Use In Babies Below 2 Months ↗
The FDA has granted priority review for Genentech's, a unit of Roche Holdings AG (OTC: RHHBY) supplemental marketing application for Evrysdi (... 
Via Benzinga
News headline image
These OTC Securities Had the Most Trading Activity in December ↗
This post contains sponsored advertising content. This content is for informational purposes only and is not intended to be i... 
Via Benzinga
News headline image
Genentech’s Evrysdi (risdiplam) Granted FDA Priority Review for Treatment of Pre-Symptomatic Babies Under 2 Months of Age With Spinal Muscular Atrophy (SMA)
From Genentech
Via Business Wire
News headline image
The Lancet Publishes Studies Showing Genentech’s Faricimab Improved and Maintained Vision in Two Leading Causes of Vision Loss, Extending Time Between Treatments up to Four Months
From Genentech
Via Business Wire
News headline image
The Week Ahead In Biotech (Jan. 23-29): Roche, Azurity FDA Decisions, J&J, Vertex Earnings, & More ↗
Biotech stocks pulled back yet again during the week ending Jan. 21, with the sector retreating along with the broader market. The news flow tapered off following the frenetic pace of the week that... 
Via Talk Markets
News headline image
Chopped Stocks ↗
The day's theme is sell tech and buy banks. 
Via Talk Markets
News headline image
MLK Day Global News ↗
In Q4 China's GDP growth rate halved to 4%. 
Via Talk Markets
News headline image
More Serious Matters ↗
Wall Street fell on new worries about inflation and a drop in retail sales levels. 
Via Talk Markets
Breast Cancer Treatment Advancements Emerge After New Study Finds Global Deaths Increased in 2019
FN Media Group Presents USA News Group News Commentary Vancouver, BC – January 14, 2022 – USA News Group – Cancer cases are on the rise, according to a new study comparing the number of cancer... 
Via FinancialNewsMedia
Topics Death
News headline image
Interest Rate Hikes And Stocks ↗
Abnormal flooding in northwest Brazil has blocked iron ore mining which resulted in a jump in the price of ore. 
Via Talk Markets
News headline image
CMS Proposes Coverage Of Biogen's Alzheimer's Drug, With Conditions Apply ↗
The Centers for Medicare & Medicaid Services (CMS) released a proposed national coverage determination for Medicare to cover drugs that target amyloid for mild... 
Via Benzinga
News headline image
Happy New Year - Sunday Edition ↗
Starting a new year - we look at tech, pharma and mining stocks and their goings-on. 
Via Talk Markets
News headline image
Attention Biotech Investors: Mark Your Calendar For January PDUFA Dates ↗
Regulatory decisions by the U.S. Food and Drug Administration in December turned out to be mostly positive. Among the treatment options that were greenlighted in the month were... 
Via Benzinga
News headline image
Healthcare Stocks Are Winners And Provide Diversification To Your Portfolio ↗
As we have written their year many times speculative small cap biotechs have not done well in 2021 since they peaked in February. 
Via Talk Markets
News headline image
Boxing Day Finance ↗
Today we saw the Dow Jones move up over 36,000. 
Via Talk Markets
News headline image
Free COVID Tests: What Stocks Will Benefit? ↗
The government hasn’t announced yet what company or companies it will be buying from, but there are several businesses involved in producing these kits. 
Via Talk Markets
News headline image
Biotech Playbook 2021 Part 2: Rotation Rally Brings Relief after FED Pivot ↗
The new aggressive Fed taper combined with a rise in interest rates for 2022 adds a new element of risk to portfolio management. Monetary policy is a headwind for 2022. 
Via Talk Markets
News headline image
Dreaming Of A Red Christmas ↗
The stock market is reacting with lots of selling to the weekend's news. 
Via Talk Markets
News headline image
Lineage, Genentech Ink Cell Therapy Licensing Pact For Ocular Diseases ↗
Lineage Cell Therapeutics Inc (NYSE: LCTX) has entered into an exclusive worldwide collaboration and license agreement with Roche Holdings AG's (OTC: RHHBY)... 
Via Benzinga
News headline image
Raising Rates ↗
The Bank of England raised its interest rate to 0.25%, setting a pattern for other countries. 
Via Talk Markets
News headline image
These OTC Securities Had the Most Trading Activity in November ↗
Photo by Markus Winkler on Unsplash The following post was written and/or published as a collaboration between Benzinga’s in-house sponsored content team and a financial... 
Via Benzinga
News headline image
The Daily Biotech Pulse: Calliditas Snags FDA Nod, Novartis to Buy Back $15B In Shares, Valneva Touts Vaccine Data, Immix, Bionomics Debut On Wall Street ↗
Here's a roundup of top developments in the biotech space over the last 24 hours: Stocks In Focus Calliditas Gets Conditional Approval For Kidney Inflammation Disease Drug... 
Via Benzinga
News headline image
Novartis Launches New Share Buyback Program Of Up To $15B ↗
Novartis AG (NYSE: NVS) is launching a new share buyback worth up to $15 billion to be executed by the end of 2023, adding it was confident in its top-line growth... 
Via Benzinga
News headline image
After Roche Walks Away, Atea Puts Break On Late-Stage COVID-19 Oral Antiviral Trial ↗
Atea Pharmaceuticals Inc (NASDAQ: AVIR) said it would close the global Phase 3 MORNINGSKY trial. The decision comes after considering the changing COVID-19 landscape... 
Via Benzinga
News headline image
Roche's Polivy Combo Boosts Survival In Early-Stage Lymphoma Patients ↗
Roche Holdings AG (OTC: RHHBY) announced results from the Phase 3 POLARIX study of Polivy (polatuzumab vedotin) with MabThera/Rituxan (rituximab) and the chemotherapy regimen... 
Via Benzinga
News headline image
Genentech’s Polivy Combination Reduced the Risk of Disease Worsening or Death by 27% in People With Previously Untreated Aggressive Form of Lymphoma
From Genentech
Via Business Wire
< Previous 1 2
...
24 25 26 27 28 29 30 31 32
...
36 37 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.